Sta edoxaban calibrator

Manufactured by Stago

Sourced in United States, France

The STA®Edoxaban calibrator is a laboratory reagent used to calibrate and validate the performance of coagulation analyzers when measuring edoxaban levels in patient samples. It provides a standardized solution with known edoxaban concentrations to ensure accurate and reliable test results.

Automatically generated - may contain errors

Lab products found in correlation

Sta edoxaban control, by Stago (2 mentions) Hemosil liquid heparin, by Werfen (1 mentions) Sta r evolution, by Stago (1 mentions) Sta liquid anti xa, by Stago (1 mentions)

2 protocols using sta edoxaban calibrator

Comparative Analysis of Edoxaban Anti-Xa Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-Xa activity was measured prospectively on Days 1, 4, 8 and 15. Blood was drawn one hour after drug intake on Days 1, 4 and 8 and 12 h after the last drug intake on Day 15.
The anti-Xa activity of edoxaban was measured using (i) Testzym^ⓇHeparin S (Sekisui Medical Co., Ltd., Tokyo, Japan) on the Coagrex^Ⓡ 800 System (Sekisui; assay A) [15 (link), 19 (link)]; (ii) STA®-Liquid Anti-Xa (Stago, Asnières-sur-Sreine, France) on STA^Ⓡ-R Evolution® coagulometer (Stago; assay B) with a dedicated test set-up [21 (link)]; and (iii) HemosIL® Liquid Heparin (Instrumentation Laboratory; Bedford, MA, USA) on ACL-TOP® (Instrumentation Laboratory; assay C) [21 (link), 22 (link)].
Assay A was calibrated using a fondaparinux-specific standard and results were expressed in fondaparinux mg/L. Assay B was calibrated using a edoxaban-specific calibrator set (STA®Edoxaban calibrator) and verified using an edoxaban-specific control set (STA®Edoxaban Control), both developed by Stago. Assay C was calibrated using the HemosIL Liquid Heparin Calibrator (Instrumentation Laboratory). Results for assay C were expressed in heparin international units (IU)/mL. Assay A contains additional antithrombin (AT) in the assay system, while assays B and C do not.

Ikejiri M., Wada H., Tone S., Wakabayashi H., Hasegawa M., Matsumoto T., Fujimoto N., Yamada N., Ito M., Nakatani K, & Sudo A. (2017). Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant. Thrombosis Journal, 15, 27.

+ Open protocol

+ Expand

Quantifying Direct Xa Inhibitor Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

The concentration of direct anti-Xa inhibitors in the patient's plasma will be inferred from the one-stage chromogenic assay STA-Liquid Anti-Xa assay (Stago Deutschland GmbH, Düssedlorf, Germany), which is used together with a drug-specific calibrator and control (STA-Apixaban Calibrator and STA-Apixaban Control, STA-Rivaroxaban Calibrator and STA-Rivaroxaban Control, STA-Edoxaban Calibrator and STA-Edoxaban Control, Stago, Asnières-sur-Seine, France). Chromogenic tests measure the capacity of residual factor Xa of the patient's plasma to hydrolyze a chromogenic substrate by measuring the change in optical density per minute, which is inversely correlated with the concentration of direct Xa inhibitor in the patient's plasma. After plotting a drug-specific calibration curve with anti-Xa activity (IU/mL) on the
y-axis and the concentration of the respective direct Xa inhibitor (ng/mL) on the
x-axis, the concentration of the respective direct Xa inhibitor in the patient's plasma can be inferred from the calibration curve. The lower detection limit is 25 ng/mL for rivaroxaban, 20 ng/mL for apixaban, and 10 ng/mL for edoxaban.

Sedghi A., Heubner L., Klimova A., Tiebel O., Pietsch J., Mirus M., Barlinn K., Minx T., Beyer-Westendorf J., Puetz V., Spieth P, & Siepmann T. (2022). Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study. Thrombosis and Haemostasis, 122(11), 1954-1962.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!